Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

Published Date: 23 Mar 2026

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Read Full News

Latest News

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Antibiotic Stewardship: Five Tips to Reduce Resistance

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

Todays Updates

Sanofi Says Rare Lung Disease Drug Outperforms Standard Care in Trial

(Corrects executive's name from Alaa Ahmed to Alaa Hamed in paragraphs 7 and 8)

Advance Directives When Suicide Is Involved: Ethicist

Ethicist Art Caplan discusses a recent case involving attempted suicide and advance directives

Spinal Anesthesia for Circumcision Tops General Anesthesia

Spinal anesthesia offers faster recovery, similar OR time, and significantly less opioid use, with no increase in cost or OR delays.

Single Bevacizumab Dose Sustains Trabeculectomy Success

A single injection of bevacizumab given during glaucoma surgery is associated with improved chances of surgical success even 3 years after the operation, a follow-up study of a clinical trial shows.

US States Reject Anti-vaccine Bills as Public Health Groups Fight MAHA

Dozens of state anti-vaccine bills backed by "Make America Healthy Again" supporters have failed after public health groups won over Republican state lawmakers, marking a...

US Health Department Withdraws Vaccine Advisory Panel Charter

The U.S. health department has withdrawn an April charter renewal for a key vaccine ⁠advisory panel that laid out new membership rules and direction, citing an...

Britain Gets Experimental Drug From Japan to Bolster Hantavirus Response

Britain has received supplies of the antiviral drug favipiravir from Japan as part of its response to a deadly hantavirus ⁠outbreak linked to the Hondius cruise liner, the...

Todays Updates

Sanofi Says Rare Lung Disease Drug Outperforms Standard Care in Trial

(Corrects executive's name from Alaa Ahmed to Alaa Hamed in paragraphs 7 and 8)

Advance Directives When Suicide Is Involved: Ethicist

Ethicist Art Caplan discusses a recent case involving attempted suicide and advance directives

Spinal Anesthesia for Circumcision Tops General Anesthesia

Spinal anesthesia offers faster recovery, similar OR time, and significantly less opioid use, with no increase in cost or OR delays.

Single Bevacizumab Dose Sustains Trabeculectomy Success

A single injection of bevacizumab given during glaucoma surgery is associated with improved chances of surgical success even 3 years after the operation, a follow-up study of a clinical trial shows.

US States Reject Anti-vaccine Bills as Public Health Groups Fight MAHA

Dozens of state anti-vaccine bills backed by "Make America Healthy Again" supporters have failed after public health groups won over Republican state lawmakers, marking a...

US Health Department Withdraws Vaccine Advisory Panel Charter

The U.S. health department has withdrawn an April charter renewal for a key vaccine ⁠advisory panel that laid out new membership rules and direction, citing an...

Britain Gets Experimental Drug From Japan to Bolster Hantavirus Response

Britain has received supplies of the antiviral drug favipiravir from Japan as part of its response to a deadly hantavirus ⁠outbreak linked to the Hondius cruise liner, the...

Latest News

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

News All Time

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

QOL Maintained With Giredestrant Combo in Advanced BC

Giredestrant plus everolimus does not increase treatment burden in advanced breast cancer, new safety and patient-reported outcome data from the evERA BC trial show.

De-escalation Misses the Mark in Inflammatory Breast Cancer

Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

Recommended News For You

RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

Lung nodules seen in a high percentage of non-smokers

AI Model as Effective as Radiologists in Detecting Prostate Cancer on MRI

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.

Recommended Articles For You

Interpreting Iron Studies: What Your Blood Results Really Mean  

Liquid Biopsy: Revolutionizing Precision Oncology in Hematological Malignancies 

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025 

The Unseen Danger of Anal Cancer: How to Protect Yourself 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More nonsmokers are getting lung cancer: Oncologist explains why

2.

FDA Approves CAR-T Product Use for Myeloma Early.

3.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

4.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

5.

ALK-positive lung cancer trial results show unprecedented progression-free survival.

1.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

2.

Understanding the Role of CA 19-9 in Cancer Diagnosis and Treatment

3.

Beating Cancer Fatigue The Most Effective Exercise Strategies for Breast Cancer Survivors

4.

Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact

5.

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

5.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot